Inhibitex has filed a registration statement with the Securities and Exchange Commission for an initial public offering (IPO) reportedly worth as much as $86.3 million.
The number of shares to be offered and at what price has not yet been determined, but the company said it intends its common stock to list on the Nasdaq under the ticker symbol “INHX”
Piper Jaffray and Lazard will act as joint book-running managers, with Thomas Weisel Partners acting as a co-manager for the IPO. The offering will be made only by means of a prospectus.
Inhibitex is a biopharmaceutical company engaged in the discovery, development and commercialization of novel antibody-based products for the prevention and treatment of serious bacterial and fungal infections in the hospital setting.
The Atlanta-based company currently has two product candidates in late-stage clinical development, and three product candidates in preclinical development.